BRAF and melanoma: In combination with RAF kinase inhibitors, it synergistically inhibits Braf (v-raf murine sarcoma viral oncogene homolog B1) mutated melanoma cell proliferation [92], and in combination with anaplastic lymphoma kinase (ALK) inhibitors, it synergistically inhibits ALK mutated neuroblastoma and prolongs survival.